These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 25251967)

  • 1. Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion.
    Weinstock C; Möhle R; Dorn C; Weisel K; Höchsmann B; Schrezenmeier H; Kanz L
    Transfusion; 2015 Mar; 55(3):605-10. PubMed ID: 25251967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
    Gupta S; Fenves A; Nance ST; Sykes DB; Dzik WS
    Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discriminating complement-mediated acute transfusion reaction for type O+ red blood cells transfused into a B+ recipient with the complement hemolysis using human erythrocytes (CHUHE) assay.
    Cunnion KM; Hair PS; Krishna NK; Whitley PH; Goldberg CL; Fadeyi EA; Maes LY
    Transfusion; 2016 Jul; 56(7):1845-8. PubMed ID: 26997226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
    Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
    J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute hemolysis of transfused A2 red cells by an auto-HI antibody.
    Darabi K; Makar RS
    Transfusion; 2008 May; 48(5):964-8. PubMed ID: 18454737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe haemolysis and renal failure in a patient with paroxysmal nocturnal haemoglobinuria.
    Jackson GH; Noble RS; Maung ZT; Main J; Smith SR; Reid MM
    J Clin Pathol; 1992 Feb; 45(2):176-7. PubMed ID: 1541704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
    Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
    Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unusual response to ABO incompatible blood transfusion.
    Buchholz DH; Bove JR
    Transfusion; 1975; 15(6):577-82. PubMed ID: 1198685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide inhibitor of complement C1 modulates acute intravascular hemolysis of mismatched red blood cells in rats.
    Kumar PS; Pallera HK; Hair PS; Rivera MG; Shah TA; Werner AL; Lattanzio FA; Cunnion KM; Krishna NK
    Transfusion; 2016 Aug; 56(8):2133-45. PubMed ID: 27282513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
    Hill A; Rother RP; Arnold L; Kelly R; Cullen MJ; Richards SJ; Hillmen P
    Haematologica; 2010 Apr; 95(4):567-73. PubMed ID: 20145265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma exchange in acute hemolytic reaction due to ABO-incompatible erythrocyte concentrate transfusions: Single center experience.
    Andıç N; Teke HÜ; Gündüz E
    Transfus Med; 2023 Oct; 33(5):409-412. PubMed ID: 37379860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemolytic transfusion reaction due to anti-IH.
    Irani MS; Richards C
    Transfusion; 2011 Dec; 51(12):2676-8. PubMed ID: 21658050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
    Nilsson PH; Thomas AM; Bergseth G; Gustavsen A; Volokhina EB; van den Heuvel LP; Barratt-Due A; Mollnes TE
    Mol Immunol; 2017 Sep; 89():111-114. PubMed ID: 28610663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biphasic clearance of incompatible red blood cells through a novel mechanism requiring neither complement nor Fcγ receptors in a murine model.
    Liepkalns JS; Hod EA; Stowell SR; Cadwell CM; Spitalnik SL; Zimring JC
    Transfusion; 2012 Dec; 52(12):2631-45. PubMed ID: 22502635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
    Josephson CD; Castillejo MI; Grima K; Hillyer CD
    Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation.
    Biglarnia AR; Nilsson B; Nilsson T; von Zur-Mühlen B; Wagner M; Berne C; Wanders A; Magnusson A; Tufveson G
    Transpl Int; 2011 Aug; 24(8):e61-6. PubMed ID: 21696455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe hemolytic anemia due to multiple red cell alloantibodies after an ABO-incompatible allogeneic bone marrow transplant.
    López A; de la Rubia J; Arriaga F; Jiménez C; Sanz GF; Carpio N; Marty ML
    Transfusion; 1998 Mar; 38(3):247-51. PubMed ID: 9563404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.
    Risitano AM; Notaro R; Marando L; Serio B; Ranaldi D; Seneca E; Ricci P; Alfinito F; Camera A; Gianfaldoni G; Amendola A; Boschetti C; Di Bona E; Fratellanza G; Barbano F; Rodeghiero F; Zanella A; Iori AP; Selleri C; Luzzatto L; Rotoli B
    Blood; 2009 Apr; 113(17):4094-100. PubMed ID: 19179465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy.
    Yazdanbakhsh K; Kang S; Tamasauskas D; Sung D; Scaradavou A
    Blood; 2003 Jun; 101(12):5046-52. PubMed ID: 12576307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. White cell-associated procoagulant activity induced by ABO incompatibility.
    Davenport RD; Polak TJ; Kunkel SL
    Transfusion; 1994; 34(11):943-9. PubMed ID: 7974702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.